Related Experiment Video

Updated: Sep 28, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Erlotinib OSI/Roche/Genentech

Tracy E Kim1, John R Murren

  • 1Yale University School of Medicine, 333 Cedar St, New Haven, CT 06520, USA. tracykim@snet.net

Current Opinion in Investigational Drugs (London, England : 2000)
|December 25, 2002
PubMed

Insights

Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, is being developed for solid tumors. Clinical trials are underway for non-small-cell lung cancer and pancreatic cancer.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Erlotinib (CP-358774, OSI-774, Tarceva) is an orally active quinazoline derivative.
  • It functions as an epidermal growth factor receptor tyrosine kinase inhibitor.

Purpose of the Study:

  • To evaluate erlotinib as a potential treatment for solid tumors.
  • To assess its efficacy in monotherapy and combination therapy.

Main Methods:

  • Development of erlotinib is most advanced in non-small-cell lung cancer (NSCLC) and pancreatic cancer.
  • Phase III trials for NSCLC combination therapy began in July 2001.
  • Phase III trials for NSCLC monotherapy and pancreatic cancer combination therapy commenced in October 2001.
  • Phase I studies in Japan were initiated in January 2002.

Main Results:

  • Erlotinib is under joint development by Genentech, OSI, and Roche.
  • The compound is being investigated for various solid tumors including breast, head and neck cancers.

Conclusions:

  • Erlotinib shows promise for treating non-small-cell lung cancer and pancreatic cancer.
  • Ongoing clinical trials will further define its therapeutic role.

More Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...